BACKGROUND: There is limited data on the use of thromboprophylaxis in patients with advanced cancer. We therefore aimed to study the practice of thromboprophylaxis in palliative care units in Austria. METHODS: We monitored use, indication, and contraindications to thromboprophylaxis in 134 patients hospitalized in 21 palliative care units in a prospective, cross-sectional study. RESULTS: Forty-seven percent of patients were on low molecular weight heparin on the day of the study for primary or secondary thromboembolism. Thromboprophylaxis had been withdrawn in 18% of the patients upon admission to the palliative care unit. Contraindications for thromboprophylaxis were present in 27% of all patients. Cancer was present in 86% of the patients. The use of thromboprophylaxis was similar in cancer patients and in non-cancer patients (49% vs. 42%). Contraindications for thromboprophylaxis were present in 24% of all cancer patients. Significantly more bedridden cancer patients had contraindications for prophylaxis when compared with mobile cancer patients (35% vs. 16%; p = 0.03). Low performance status was by far the most frequent contraindication among these patients (89%). Seventy-one percent of all bedridden cancer patients were treated in accordance with common guidelines for thromboprophylaxis when contraindications were taken into account. Eighty-seven percent of patients who had been involved in decision making opted for getting prophylaxis. CONCLUSIONS: Our data reveal that about half of all cancer patients in palliative care units are treated with thromboprophylaxis. Low performance status was the most frequent contraindication for thromboprophylaxis.
BACKGROUND: There is limited data on the use of thromboprophylaxis in patients with advanced cancer. We therefore aimed to study the practice of thromboprophylaxis in palliative care units in Austria. METHODS: We monitored use, indication, and contraindications to thromboprophylaxis in 134 patients hospitalized in 21 palliative care units in a prospective, cross-sectional study. RESULTS: Forty-seven percent of patients were on low molecular weight heparin on the day of the study for primary or secondary thromboembolism. Thromboprophylaxis had been withdrawn in 18% of the patients upon admission to the palliative care unit. Contraindications for thromboprophylaxis were present in 27% of all patients. Cancer was present in 86% of the patients. The use of thromboprophylaxis was similar in cancerpatients and in non-cancerpatients (49% vs. 42%). Contraindications for thromboprophylaxis were present in 24% of all cancerpatients. Significantly more bedridden cancerpatients had contraindications for prophylaxis when compared with mobile cancerpatients (35% vs. 16%; p = 0.03). Low performance status was by far the most frequent contraindication among these patients (89%). Seventy-one percent of all bedridden cancerpatients were treated in accordance with common guidelines for thromboprophylaxis when contraindications were taken into account. Eighty-seven percent of patients who had been involved in decision making opted for getting prophylaxis. CONCLUSIONS: Our data reveal that about half of all cancerpatients in palliative care units are treated with thromboprophylaxis. Low performance status was the most frequent contraindication for thromboprophylaxis.
Authors: Suzie Gillon; Simon Noble; Jason Ward; Keri-Michele Lodge; Anne Nunn; Sim Koon; Miriam J Johnson Journal: Palliat Med Date: 2011-02-10 Impact factor: 4.762
Authors: Ajay K Kakkar; Mark N Levine; Zbigniew Kadziola; Nicholas R Lemoine; Vanessa Low; Heman K Patel; Gordon Rustin; Michael Thomas; Mary Quigley; Robin C N Williamson Journal: J Clin Oncol Date: 2004-05-15 Impact factor: 44.544
Authors: Alok A Khorana; Michael B Streiff; Dominique Farge; Mario Mandala; Philippe Debourdeau; Francis Cajfinger; Michel Marty; Anna Falanga; Gary H Lyman Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Christina A Kowalewska; Brie N Noble; Erik K Fromme; Mary Lynn McPherson; Kristi N Grace; Jon P Furuno Journal: J Palliat Med Date: 2017-06-05 Impact factor: 2.947
Authors: Clare White; Simon I R Noble; Max Watson; Flavia Swan; Victoria L Allgar; Eoin Napier; Annmarie Nelson; Jayne McAuley; Jennifer Doherty; Bernadette Lee; Miriam J Johnson Journal: Lancet Haematol Date: 2019-02 Impact factor: 18.959